Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. As of March 4, 2025, the average one-year ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering. Mineralys intends to use the net proceeds from the proposed offering to fund clinical ...